Recently, the valuation of Regeneron Pharmaceuticals (REGN) increased following a 16% share price rally, with a subsequent boost in stake by several investment groups such as Grandfield & Dodd LLC and KBC Group NV amidst other investment activities as witnessed by ABN Amro Investment Solutions and Vise Technologies Inc. Regeneron reported positive Phase 2 and 3 data across key clinical programs with a 5.8% price rise, on addition to gaining attention from the successful Phase 3 Garetosmab Trial for Rare Disease and two positive Phase 3 trials on allergies.
There was also an announcement of new clinical data on its drugs Lynozyfic™ and Odronextamab. Despite taking a significant tax hit, Regeneron's earnings surpassed expectations, and it also gained a positive opinion from the European Medicines Agency on Libtayo. Moreover, the U.S. Food and Drug Administration (FDA) approved Linvoseltamab for multiple myeloma, resulting in a price target lift. However, not all news was positive as there were instances of guards selling shares, margin dips and a decrease in the stock position by some investors.
Regeneron Pharmaceuticals REGN News Analytics from Thu, 07 Aug 2025 07:00:00 GMT to Sat, 15 Nov 2025 13:24:21 GMT - Rating 6 - Innovation -3 - Information 7 - Rumor -5
